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Effects of sulfonylureas, a-endosulfine counterparts, on
glomerulosclerosis in type 1 and type 2 models of diabetes.
Background. Previously, we showed the expression of a
unique sulfonylurea receptor (SUR) and its putative endoge-
nous ligand, a-endosulfine, in mesangial cells and isolated
glomeruli. Further, this ligand was up-regulated by high glucose
concentration. To investigate the possible role of a-endosulfine
up-regulation in diabetes, we administered sulfonylureas, the
exogenous ligands of SUR, to diabetic animals.
Methods. In streptozotocin-induced, insulin-deficient, dia-
betic rats, glomerulosclerosis, albuminuria, glomerular expres-
sion of fibronectin mRNA, and glomerular filtration rate (GFR)
were studied for various periods up to 36 weeks. Several rat
groups received either glibenclamide or tolazamide during the
entire study period. Also, glomerulosclerosis and albuminuria
were determined in insulin-resistant db/db mice, at 26 weeks of
treatment with tolazamide.
Results. Sulfonylureas did not improve hyperglycemia or re-
duce glycosylated hemoglobin levels. In insulin-deficient dia-
betic rats, sulfonylureas significantly decreased the degree of
glomerulosclerosis and completely reversed the enhanced albu-
min excretion. Also, glibenclamide reduced diabetes-induced
glomerular overexpression of fibronectin mRNA. Because
glibenclamide may improve the afferent arteriolar dilatation of
diabetes, thereby reducing glomerular hyperfiltration, its effect
on GFR was determined. Glibenclamide did not alter glomeru-
lar hyperfiltration or renal hypertrophy, regardless of the
intensity of hyperglycemia. Finally, in insulin-resistant mice, to-
lazamide did not alter the extent of diabetic glomerulosclerosis
or increased albuminuria.
Conclusion. Long-term treatment with sulfonylureas com-
pletely prevents glomerular injury in insulin-deficient diabetes
in rats. However, this protective effect is not demonstrable in an
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insulin-resistant model of the disease. We postulate that mesan-
gial a-endosulfine up-regulation in the hyperglycemic milieu of
insulin-deficient diabetes may retard glomerular extracellular
matrix formation and mesangial expansion.
Sulfonylureas act on adenosine triphosphate (ATP)-
sensitive K+ channels (KATP). The membrane-bound
pancreatic b cell KATP has been most extensively studied
and represents the “classic” KATP [1–3]. Classic KATPs
consist of two structurally unrelated subunits: a potas-
sium pore and a sulfonylurea receptor (SUR). The pore
belongs to the Kir6.x subfamily of weak inwardly recti-
fying K+ channels while SUR is a member of the ATP-
binding cassette (ABC) superfamily [4, 5]. Functional b
cell KATPs are tetradimers of Kir.6.2/SUR1 [6] in which
Kir6.2 confers KATP inhibition by ATP and SUR in-
creases pore sensitivity to ATP, and regulates channel ac-
tivation by magnesium adenosine diphosphate (MgADP)
and sulfonylureas [3]. Thus, sulfonylurea binding to SUR
inhibits the channel and closes the ion pore. The con-
sequent cell membrane depolarization and Ca2+ influx
through voltage-gated channels mediates insulin secre-
tion.
Nearly 90% of the cellular KATPs are not localized to
the plasmalemma, but to the endoplasmic reticulum, mi-
tochondria, and secretory granules [7–10]. Consequently,
nearly 70% of all sulfonylurea binding is cytosolic, and
this intracellular locus of action of KATP appears to be an
important determinant of the action of sulfonylureas [11].
Notably, the sulfonylurea membrane-binding site of the
b cell KATP is cytosolic, implying the requisite membrane
translocation of exogenously applied sulfonylurea to in-
voke its action [12] and these observations reconcile the
greater potency of the more highly lipophilic sulfonylurea
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compounds [13, 14]. Thus, all SUR ligands are intracellu-
lar.
The extrapancreatic SUR isoforms are the low-affinity
SUR2 isoforms SUR2A and SUR2B [15–17]. SUR2B is
widely expressed in the kidney, particularly in proximal
tubule, ascending limb, and the collecting duct where
it presumably mediates, in part, K+ transport [18–20].
In addition, high- and low-affinity sulfonylurea-binding
components are also present in isolated, metabolically
active glomeruli [21]. In regard to glomerular vascu-
lar reactivity, the sulfonylurea glibenclamide reverses
the hypocontractility of diazoxide-dilated afferent arte-
rioles via KATP activation [22], and in streptozotocin-
induced diabetic animals, glibenclamide produced a
concentration-dependent decrease in the pathologically
exaggerated afferent arteriolar diameter [23]. Therefore,
sulfonylureas may potentially induce renal metabolic and
functional effects that include amelioration of diabetic
glomerular hypertension.
Pharmacologic studies have demonstrated the diver-
sity of KATP among various tissues, according to their
sulfonylurea affinity and sensitivity to K+ channel open-
ers [24]. These heterogeneous functional characteristics
are based upon differing complexations of Kir6.x and
SUR isoforms. Recently, we characterized a functional
rat mesangial KATP containing a previously undescribed
rat mesangial SUR2 splice variant [25, 26]. Expression of
this novel mesangial SUR2 protein was shown in primary
and cloned mesangial cell lines (16KC2) with a specific
antibody that reacted with the common C-terminal epi-
tope of SUR2A and SUR2B.
a-Endosulfine, a putative endogenous ligand of SUR,
has been recently isolated [27, 28]. The gene encoding
this protein (ENSA) is constitutively expressed in many
tissues [29, 30], and a-endosulfine represents one of a
family of neuronal cyclic adenosine monophosphate
(AMP)-regulated phosphoproteins (ARPPs). These pro-
teins are without known enzymatic activity, but possess
characteristics common to intracellular proteins that al-
ter the activities of enzymes involved in signal transduc-
tion [e.g., calmodulin and the protein kinase A inhibitor
(Walsh inhibitor) protein kinase I] [31]. Of these ARPPs,
two closely related isoforms have been characterized by
apparent molecular mass (ARPP-16 and ARPP-19) [31],
and these are capable of competitive inhibition of sul-
fonylurea binding to its target tissues [29, 30]. To date,
only the ARPP-19/e, a-endosulfine, has been well char-
acterized, although its actions remain largely unknown
[31]. It has been proposed that a-endosulfine does not
mediate its actions in an autocrine or paracrine fashion
but by regulating intracellular signaling [32–34].
In recent work, we have demonstrated the ENSA and
a-endosulfine expression in rat glomeruli and cultured
rat mesangial cells [35]. Further, gene and protein expres-
sion were up-regulated in parallel during the exposure of
mesangial cells to a high glucose concentration. There-
fore, glomerular cells express all the components of an
a-endosulfine/KATP system that is regulatable by glucose.
In the present study, the potential glomerular effects of a-
endosulfine in vivo have been explored by mimicking its
up-regulation by the chronic administration of a sulfony-
lurea. Because sulfonylureas are not expected to enhance
insulin secretion in diabetes induced by pancreatic b-cell
injury with streptozotocin, this experimental model of-
fered the opportunity of studying the direct glomerular
effects of these drugs in the absence of the confounding
metabolic effects of hyperinsulinemia. In addition, since
sulfonylureas are extensively used in the treatment of
type 2 diabetes, their effects in an insulin-resistant animal
model of this disease, db/db mice, were also investigated.
METHODS
Materials
Streptozotocin, glibenclamide, tolazamide, fluorescein
isothiocyanate (FITC)-inulin, dextran T-40, ribonucle-
oside vanadyl complex, and total glycated hemoglobin
kits (#442) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Novolin N (NPH) (human insulin
isophane suspension) and Linplant insulin implants
were purchased from Novo Nordisk Pharmaceutical In-
dustries (Clayton, NC, USA) and Linshin Canada Inc.
(Scarborough, Ontario, Canada), respectively. Metho-
hexital (Brevital) and isofluorane (Forane) were
obtained from Eli Lilly & Co. (Indianapolis, IN, USA)
and Baxter (Deerfield, IL, USA), respectively. Albumin-
uria was assessed with the Nephrat and the Creatinine
Companion kits obtained from Exocell Inc. (Philadel-
phia, PA, USA). Rabbit antirat albumin antibody was
purchased from ICN Biomedical (Aurora, OH, USA).
Ambion (Austin, TX, USA) supplied the RNase inhibitor
SUPERaseIN. Qiagen Inc. (Valencia, CA, USA) pro-
vided the following kits for mRNA purification and quan-
tification: RNeasy Mini Kit, RNase-free DNase Set, and
Quantitect Probe RT-PCR Kit. Primers and probes were
purchased from TIB-Molbiol LLC (Adelphia, NJ, USA).
Animals
Simonsen Laboratories (Gilroy, CA, USA) and Jack-
son Laboratories (Bar Harbor, ME, USA) supplied the
rats and mice, respectively. Studies were carried out ac-
cording to protocols approved by the Institutional An-
imal Care and Use Committee of Henry Ford Health
Sciences Center. Insulin-deficient diabetes was induced
in male Munich-Wistar rats at age 4 to 5 weeks old by a
single intravenous dose of 55 mg/kg streptozotocin, dis-
solved in sodium citrate buffer-acidified normal saline,
via the dorsal penile vein. This dose of streptozotocin re-
sults in significantly impaired ability to produce insulin
and moderate to severe hyperglycemia. Long-term sur-
vival in most animals occurs without insulin treatment.
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Control animals received the same volume of solution
vehicle. Postprandial (morning) blood glucose and body
weight measurements were obtained twice weekly for 2
weeks then once every 3 to 4 weeks during the rest of
the study. In renal function and gene expression stud-
ies, a blood sample was obtained for determination of
glycosylated hemoglobin at the completion of the ob-
servation period. Genetically diabetic male obese mice
(C57BLKS db/db) and their nondiabetic heterozygous
lean controls (db/+) entered the study at 4 weeks old,
when obesity and hyperglycemia become evident in the
diabetic group. Blood glucose measurements were ob-
tained during weeks 3 to 4 and at conclusion of experi-
ments.
Treatment protocols
Group 1 rats not regularly treated with insulin. The
goal was to maintain a chronic significant hyperglycemia,
ranging from 350 to 500 mg/dL. Rats in group 1 were used
as diabetic controls in renal function studies, in glomeru-
lar gene expression quantification studies at 14 and 22
weeks of diabetes, respectively, and in histologic stud-
ies at 36 weeks after disease induction. Since glomeru-
lar hyperfiltration has been reported at various intervals
between 1 and 44 weeks [36, 37] after streptozotocin in-
jection, renal functional changes and hypertrophy were
expected to be well established by 14 weeks of diabetes,
when there is no significant glomerular injury. Similarly, a
period of 22 weeks was selected for gene expression quan-
tification because glomerular extracellular matrix mRNA
expression has been reported to be increased between 16
and 24 weeks of experimental diabetes in rats and before
the onset of glomerulosclerosis [38, 39]. Histologic stud-
ies were designed to evaluate the initial manifestations of
morphologic glomerular disease. Although mesangial ex-
pansion is morphometrically detectable at 24 weeks after
induction of the disease [40], a difference in the preva-
lence of glomerulosclerosis between diabetic animals and
age-matched controls has only been reported by light mi-
croscopy at 38 to 56 weeks of the disease in animals par-
tially treated with insulin [41, 42]. Histologic studies were
not carried out at longer periods of diabetes because after
36 weeks there is a rapid decline in the survival of animals
not regularly treated with insulin.
Although the dose of streptozotocin employed resulted
in hyperglycemia levels that were within the desired
range without insulin administration, 15% of the animals
presented, a twice-confirmed blood glucose level of 600
mg/dL or greater during the last 4 to 8 weeks of the study.
To maintain a similar degree of hyperglycemia in all an-
imals and to avoid malnutrition and weight loss during
long-term diabetes, these severely hyperglycemic animals
received a single, sustained-release subcutaneous insulin
implant (one third of a 7 mm long cylindric Linplant.
This implant reduced blood glucose to levels of 350 to
450 mg/dL for the remainder of the observation period.
All other animals did not receive insulin at any time dur-
ing the study.
Animals in group 1 were divided into the following
treatment groups: (1) diabetic rats treated with the sul-
fonylurea tolazamide, (2) diabetic rats treated with the
sulfonylurea glibenclamide, (3) diabetic rats given the
same volume of vehicle, and (4) age-matched control
rats given the same volume of solution vehicle. As part
of this vehicle, animals in all groups received a total of
40 lL/day of dimethyl sulfoxide (DMSO). All animals
received sulfonylureas or the solution vehicle by daily
gavage from day 2 after injection of streptozotocin or
acidified saline. Sulfonylureas were suspended in DMSO,
further diluted in water and given as a 0.5 mL single
daily dose. Tolazamide and glibenclamide were admin-
istered either in doses within the human pharmacologic
ranges of 14 mg/kg and 0.28 mg/kg, respectively, or at
ninefold greater amounts (128 mg/kg and 2.52 mg/kg, re-
spectively).
Group 2 rats regularly treated with insulin to induce
moderate hyperglycemia. The goal was to induce a mod-
erate chronic hyperglycemia ranging from 220 to 320
mg/dL. This was achieved by daily subcutaneous ad-
ministration of 3 to 7 U of Novolin N insulin. Rats in
group 2 were used in renal function studies. Animals
were divided into the following treatment groups: (1) di-
abetic rats treated with 0.28 mg/kg glibenclamide, and (2)
diabetic rats given the same volume of vehicle. Gliben-
clamide and solution vehicle were administered by gav-
age as above.
Group 3 insulin-resistant diabetic db/db mice not treated
with insulin. The goal was to maintain significant chronic
hyperglycemia. No animals required insulin administra-
tion as blood glucose concentrations remained lower than
600 mg/dL. Animals in group 3 were used for histologic
analysis and albuminuria determinations at 18 and 26
weeks after study entry. Light microscopy studies were
carried out at these periods of diabetes because previous
observations by others only detected minimal mesangial
expansion at shorter intervals (10 to 12 weeks) [43, 44].
Treatments were initiated at the second week after entry
into the study and maintained for the duration of the ex-
perimental period. Mice were divided into the following
groups: (1) diabetic tolazamide-treated by gavage with
14 mg/kg or 128 mg/kg of the drug dissolved in 0.1 mL of
vehicle, (2) diabetic treated with the same volume of drug-
solution vehicle, and (3) age-matched, lean heterozygous
controls, gavaged with 0.1 mL vehicle.
Glomerular microdissection and quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Rat glomeruli were microdissected from the left renal
cortex for total RNA isolation, according to a modifi-
cation of a previously described method [45]. Following
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isofluorane/oxygen anesthesia, retrograde perfusion of
left kidneys with 50 mL of ice-cold Hank’s balanced salt
solution (HBSS), containing 3.2% dextran T40, was car-
ried out via a needle placed in the abdominal aorta below
the renal arteries. Four sagittal slices from the left kidney
were obtained and placed in 0.8 lm pore-filtered, ice-cold
HBSS containing 5% ribonucleoside vanadyl complex. A
total of 160 glomeruli were microdissected in less than
25 minutes and transferred into 50 lL of sterile,
phosphate-buffered saline (PBS) containing 2 U/lL of
RNase inhibitor. Following the addition of 350 lL of
lysis buffer (buffer RLT) (RNeasy Mini Kit), samples
were rapidly homogenized twice with 15 seconds with
a rotor-strator homogenizer fitted with a 5 mm diameter
probe (Omni lH Micro Homogenizer) (Omni Interna-
tional Inc., Warrenton, VA, USA) and stored at −70◦C.
Total glomerular RNA was isolated from glomerular
homogenates using the Qiagen’s RNeasy Mini Kit, ac-
cording to the manufacturer’s instructions. This isolation
included an on-column DNase digestion step. RNA was
stored at −70◦C prior to RT-PCR.
Rapid cycle, real-time, quantitative RT-PCR was car-
ried out using the Roche LightCycler (Roche Molecu-
lar Biochemicals, Indianapolis, IN, USA), in a multiplex,
asymmetric reaction [46]. In this method, a one-step pro-
tocol was followed with the RT and PCR reactions car-
ried out sequentially in the same reaction capillary. A
commercially available reaction mix was used (Quanti-
TectTM Probe RT-PCR) supplemented with 2.5 U of Hot
Star Taq DNA polymerase (Qiagen Inc.) [47]. In multi-
plex reactions, mRNA templates of interest, fibronectin
and b-actin mRNA, were simultaneously amplified with
specific primers following reverse transcription. Product
formation was detected by fluorescence resonance en-
ergy transfer (FRET) reactions, using sequence-specific
pairs of hybridization probes labeled either with fluores-
cein or with one of two different acceptor dyes (LC-Red
640 and LC-Red 705). All primers were specifically de-
signed for intron-exon splice regions thereby preventing
any possible genomic DNA amplification. b-actin was se-
lected as the gene of reference because of the proven
stability of its expression in diabetic glomeruli [48].
Primers and probes were for fibronectin, 5′-GAGCCTT
CACACATCACCAAGTA, 5′-CATCTCCTTCCTCGC
TCAGTT, 5′-CAAAGCGAGTCACTTCTTGGTGCC
C, and 5′-LC-Red 640-TACTGCTGGATGCTGATGA
GCTGTCCC; for b-actin, 5′-ACCCACACTGTGCCC
ATCTA, 5′-GCCACAGGATTCCATACCCA, 5′-GCC
ACGCTCGGTCAGGATCTTCAT, and 5′-LC Red 705-
AGGTAGTCTGTCAGGTCCCGGCCA. Values were
calculated as arbitrary units according to results obtained
from standard curves obtained with total renal cortex
RNA, and final data was expressed as the fibronectin
mRNA/b-actin mRNA ratio in the same reaction. All
samples were analyzed in triplicate.
Renal function
Conscious, unrestrained rats had glomerular filtration
rates (GFRs) determined by a nonradioisotopic method
that combined previously described techniques [49, 50].
Osmotic minipumps, containing 10 mg/mL of FITC-
inulin diluted in PBS, were implanted subcutaneously
in rats under 37.5 mg/kg Brevital anesthesia. These
minipumps have a nominal continuous infusion rate of 10
lL/hour over 7 days, delivering 1.67 lg/minute of FITC-
inulin. Two days after minipump implantation, rats were
placed in metabolic cages, acclimatized for 24 hours and
then two successive 24-hour urine collections were ob-
tained. Following washing of rat tails to remove any uri-
nary contamination, tail vein blood samples (80 lL) were
obtained before and after each urine collection. Plasma
and urine samples were buffered by an equal volume of
1 mmol/L Hepes (pH 7.4). Inulin concentrations were
determined in duplicate, 10 lL samples by measuring flu-
orescence at wavelength of 480 nm, using the real-time
fluorimetry function of the LightCycler. Standard solu-
tions of FITC-inulin in PBS yielded linear fluorescence
between 1 lg/mL and 20 lg/mL. Plasma and urine blanks
were included to correct for background fluorescence.
GFR was calculated according to the excretion rate and
mean plasma concentration of FITC-inulin. Final results
were the mean value of the two urine and plasma collec-
tion periods. Kidneys were weighed at the conclusion of
the study.
Renal histology
Rat and mouse kidneys were perfused as above, except
that perfusion lasted for 2 minutes with HBSS perfusate
at 37◦C. In addition, perfusion volumes were reduced to
one tenth in mice. Also, immediately following this initial
period, a second perfusion with Tyrode’s buffer (pH 7.4),
containing 22.5% dextran T-40 and 3.7% paraformalde-
hyde at 37◦C, was carried out for 3 minutes for in situ fix-
ation of the tissue. The left kidney was then removed and
three, 1 mm thick slices, perpendicular to the longest kid-
ney axis, were obtained and placed in 3.7% paraformalde-
hyde in PBS at 4◦C. Tissue slices were embedded in paraf-
fin and 4 lm sections stained with periodic acid-Schiff
(PAS). The degree of mesangial expansion and glomeru-
losclerosis was semiquantitatively evaluated according to
a scoring system [51]. Three observers, masked as to the
origin of the sample, independently scored the degree
of mesangial expansion or sclerosis on a scale of 0 (no
lesion), 1+ (minimal mesangial expansion), 2+ (evident
mesangial expansion and/or basement membrane thick-
ening), 3+ (marked mesangial expansion with occasional
sclerosed lobules), and 4+ (sclerosis involving most of
the glomerular tuft). Results were expressed as preva-
lence of sclerosis (number of glomeruli with≥2+ sclerosis
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Table 1. Characteristics of the rat experimental groups included in histologic studiesa
Control Diabetic
Tolazimide Tolazamide Glibenclamide Glibenclamide
Group Treatment None None (14 mg/kg) (128 mg/kg) (0.28 mg/kg) (2.52 mg/kg)
Final number 14 57 22 21 21 24
Blood glucose 94 ± 1.3b 422 ± 9.6 416 ± 7.7 434 ± 6.7 409 ± 6.8 391 ± 7.0c
(9 months mean ± SE)
Final weight 386 ± 5.3 279 ± 5.8b 222 ± 7.0d 219 ± 4.8d 231 ± 6.4d 237 ± 4.4d
aValues are mean ± SE.
bBlood glucose concentration and body weight in all diabetic groups vs. control (P < 0.0001).
cBlood glucose concentration vs. nontreated diabetic group (P = 0.013).
dBody weight vs. nontreated diabetic group (P < 0.001).
divided by the total number of glomeruli scored in a given
specimen).
Enzyme-linked immunosorbent assay (ELISA) and
immunoblotting of urinary proteins
Rat and mouse urinary albumin was determined
from aliquots of 24-hour urine collections by a colori-
metric direct competitive ELISA (Nephrat). In rats,
urinary protein identification was carried out in pooled
collections from four animals in each experimental group
that were dialyzed against PBS and concentrated in
CentriprepTM-10 concentrators (Amicon, Beverly, MA,
USA). Equal amounts of concentrated protein (20 lg)
were dissolved in Laemmli sample buffer and resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) on Tris-glycine, 7.5% acrylamide gels,
with proteins identified by Coumassie Blue staining. In
parallel gels, resolved proteins were also transferred to a
polyvinyldene fluoride (PVDF) membranes and blocked
with TBS-T (Tris-buffered saline, pH 7.4, containing
0.05% Tween-20 and 5% skimmed milk powder). Mem-
branes were incubated overnight at 4◦C with antirat
albumin antibody, diluted in TBS-T. Bound antibody
detection was carried out using the enhanced chemi-
luminescence (ECL) analysis system (Amersham Phar-
macia Biotech UK, Little Chalfont, Buckinghamshire,
England).
Chemical analyses
Urinary creatinine was determined using the Creati-
nine Companion, a colorimetric modified alkaline pi-
crate method. The percent glycated hemoglobin content
was determined in hemolyzed whole blood samples by
affinity column separation. Total protein was quantified
with the BCA Protein Assay Kit (Pierce, Rockford, IL,
USA).
Statistical analysis
The main statistical analyses were carried out using
the StatView 5.0.1 software (Abacus Concepts Inc.,
Berkeley, CA, USA). Interrater reliability for the mean
from three raters [52] was computed using a SAS macro
(INTRACC) (SAS Institute, Cary, NC, USA). Except
where indicated, results were expressed as mean ± SE
and analyzed by analysis of variance. If significant differ-
ences were found among groups, between group com-
parisons were made with post-hoc testing by Fisher’s
protected least significant difference (PSLD) test, with
significance determined at the 5% level.
RESULTS
Effects of sulfonylureas on the development
of glomerulosclerosis in insulin-deficient diabetes
To investigate the effects of sulfonylureas on the de-
velopment of diabetic glomerulosclerosis independently
of glycemic control, streptozotocin-diabetic rats were
allowed to remain substantially hyperglycemic during
continued tolazamide or glibenclamide treatment after
disease induction. These compounds are differentiated
by their degrees of lipophilicity that presumably regulate
cell membrane translocation and association with cyto-
plasmic binding sites [14]. All diabetic animals demon-
strated a fourfold increase in their 36-week mean blood
glucose concentration over control values (Table 1). All
animals gained weight during the study period but, as ex-
pected, the weight gain was less in diabetic groups than in
controls. Sulfonylurea treatment did not improve blood
glucose levels or body weight gain in diabetic animals
as compared to the nontreated diabetic control group
(Table 1). Only animals treated with high-dosage gliben-
clamide demonstrated a small (8%) improvement in
glycemia over that in nontreated diabetic rats.
In addition to glomerular mesangial expansion,
basement membrane thickening and lobular sclerosis,
nontreated diabetic animals demonstrated occasional
glomerular vascular hyalinosis and intratubular proteina-
ceous casts. However, there was only minimal focal in-
terstitial disease. The total number of glomeruli scored
per animal by the three observers was 360 ± 71 (mean,
SD) and similar in all experimental groups. There was
a high overall reliability for the three observers av-
eraged together (interrater reliability coefficient 0.88).
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The total number of scores generated by all observers
was 53,730. As compared to age-matched normal con-
trols, 36-week diabetic, nontreated animals presented a
significant increase in the degree of glomerulosclerosis
(Fig. 1). The prevalence of glomerulosclerosis was sig-
nificantly less in the diabetic groups treated with to-
lazamide or glibenclamide than in nontreated diabetic
animals (Figs. 1 and 2). Further, this reduction in glomeru-
losclerosis appeared to be more accentuated in the groups
treated with the higher dosages, particularly in the to-
lazamide group. Notably, diabetic animals treated with
glibenclamide or high-dosage tolazamide demonstrated a
significantly lower prevalence of sclerotic glomeruli than
normal, age-matched controls (Fig. 1).
Urinary albumin excretion was significantly increased
in diabetic animals as compared to age-matched controls
(Fig. 1). In consonance with the histologic observations,
excessive albumin excretion was fully normalized in all
diabetic groups treated with sulfonylureas (Fig. 1). A re-
cent study has emphasized the possible underestimation
of urinary albumin in streptozotocin-diabetic rats as re-
sult of low-molecular-weight albumin fragments not de-
tected by radioimmunoassay [53]. Thus, there was the
theoretical possibility that, due to a modification of the al-
bumin excreted by the sulfonylurea-treated animals, sig-
nificant amounts of the protein were not detected by the
immunoassay used. To rule this out, concentrated pooled
urine samples from each of the high-dosage, sulfonylurea-
treated, and control groups were analyzed by PAGE and
immunoblotting. The protein excreted in the nontreated
and sulfonylurea-treated diabetic groups contained a sim-
ilar fraction of albumin that was immunologically de-
tectable (Fig. 3).
Effects of sulfonylureas on the glomerular expression
of fibronectin mRNA in insulin-deficient diabetes
Additional evidence of a salutary effect of sulfony-
lureas in the prevention of glomerular injury was sought
during an earlier period of diabetes when glomeruloscle-
rosis is presumed to be absent. At 22 weeks of di-
abetes, glomerular fibronectin mRNA expression was
increased over that in age-matched controls, suggesting
its increased synthesis (Fig. 4). These diabetic animals
presented significant hyperglycemia as compared to con-
trols (P < 0.0001). As before, in these animals, treatment
with glibenclamide during the entire period of diabetes
did not improve the level of hyperglycemia (control 86 ±
1.4 mg/dL; diabetic 425 ± 8.9 mg/dL; and diabetic +
glibenclamide 424 ± 7.6 mg/dL) (mean ± SE). In ad-
dition, the increased fraction of glycosylated hemoglobin
in diabetic animals (P < 0.0001) was also unaltered by the
administration of glibenclamide (control 5.4 ± 0.2%; di-
abetic 12.9 ± 0.4%; and diabetic + glibenclamide 13.2 ±
0.5%) (N = 22 to 40) (mean ± SE). However, treat-
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Fig. 1. Effect of treatment with sulfonylureas on the development of
glomerulosclerosis and albuminuria in long-term diabetic rats. The de-
gree of mesangial expansion, basement membrane thickening, and
glomerulosclerosis were independently assessed by three observers,
who were masked as to the origin of the sample, by light microscopy in
periodic acid-Schiff (PAS)-stained specimens. Studies were carried out
at 36 weeks after induction of diabetes. The degree of glomerular dis-
ease was defined on a scale of 0 to 4+. The mean value resulting from the
individual findings by the three observers (percent of glomeruli show-
ing conclusive disease) are presented. Albuminuria data correspond to
samples obtained at the end of the observation period. Each individual
albumin excretion value was the mean of two 24-hour urine collections.
Control, nontreated diabetic, tolazamide-treated, and glibenclamide-
treated diabetic animals were the same as those described in Table 1.
Values presented are mean ± SE.
ment with glibenclamide over the entire period of di-
abetes resulted in a significant reduction in fibronectin
mRNA expression compared to nontreated diabetic an-
imals, although its expression was modestly greater than
in normal controls (Fig. 4).
Effects of sulfonylureas on the renal functional changes
and hypertrophy of insulin-deficient diabetes
Sulfonylureas have been shown to restore the impaired
contractility of glomerular afferent arterioles in diabetes
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A
B
Fig. 2. Effect of treatment with sulfonylureas on diabetic glomeru-
losclerosis. Perfusion-fixed, periodic acid-Schiff (PAS)-stained kidney
specimens are shown from a nontreated diabetic animal after 36 weeks
of diabetes (A) demonstrating advanced mesangial expansion and scle-
rosis (+3) and age-matched diabetic animal that had received 0.28
mg/kg glibenclamide daily for the entire duration of diabetes (B) that
revealed only minimal mesangial disease (1+) (original magnification
×200).
[23]. To investigate whether the glomerular protective ef-
fects of sulfonylureas could be the result of decreased
glomerular mechanical strain following restoration of
glomerular pressure autoregulation and reduction of di-
abetic renal hyperfunction, experiments measuring GFR
were carried out in insulin-deficient diabetic rats with and
without treatment with glibenclamide. Studies were car-
ried out at a time when no significant glomerular diabetic
disease is apparent. Since the level of metabolic control
may determine the presence of hyperfiltration, groups of
diabetic animals, incompletely treated with daily insulin
and demonstrating moderate hyperglycemia, were also
studied. Mean blood glucose levels and the fraction of
Alb. Std.
Diab.-Tolz
Diab.-Glib
Diabetic
Control
Fig. 3. Analysis of urinary proteins in long-term diabetic animals
treated with sulfonylureas. Samples were obtained from the same urine
collections presented in Figure 1. Urine collections from four animals
in each group were pooled, dialyzed against phosphate-buffered saline
(PBS) and concentrated. Twenty micrograms of each concentrated uri-
nary protein per sample were analyzed by 7.5% sodium dodecyl sulfate-
polyacryalmide gel electrophoresis (SDS-PAGE). Immunodetection
was carried out with purified polyclonal antirat albumin antibody and
enhanced chemiluminescence (ECL) detection.
glycosylated hemoglobin were significantly higher in di-
abetic animals not treated with insulin than in controls
(Table 2). Incomplete insulin treatment resulted in de-
creased severity of the metabolic derangement with
blood glucose, glycosylated hemoglobin and weight gains
that were intermediate those of normal age-matched con-
trols and noninsulin treated diabetic animals (Table 2).
Treatment with glibenclamide did not alter the levels of
blood glucose, glycosylated hemoglobin, or final body
weight in either noninsulin-treated or insulin-treated di-
abetic groups (Table 2).
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Fig. 4. Effect of treatment with glibenclamide on diabetes-induced
glomerular overexpression of fibronectin mRNA. Twenty-two weeks
after induction of diabetes the gene expression of fibronectin was deter-
mined in samples of microdissected glomeruli by real-time, quantitative
reverse transcription-polymerase chain reaction (RT-PCR). Results are
fibronectin mRNA expression relative to b-actin mRNA expression, de-
termined in the same reaction. One sample, containing 160 glomeruli,
was analyzed per animal. Results are expressed as mean ± SE (N = 21
to 40 animals per experimental group).
Diabetic animals not receiving daily insulin demon-
strated marked hyperfiltration and renal hypertrophy
that were unchanged by treatment with glibenclamide
(Fig. 5). Amelioration of the diabetic state by incom-
plete insulin therapy decreased the magnitude of hy-
perfiltration and renal hypertrophy. Thus, in these ani-
mals, GFR was not significantly different than in controls
(Fig. 5). Again, glibenclamide administration to the
insulin-treated animals did not result in any appreciable
change in either GFR or renal hypertrophy.
Effects of sulfonylureas on the development
of glomerulosclerosis in insulin-resistant diabetes
Sulfonylureas are extensively employed in type 2 dia-
betes in humans. However, there is a lack of informa-
tion on their possible effects on the renal disease of
insulin-resistant diabetes in animal models. To explore
the effects of sulfonylureas, db/db mice were continu-
ously treated with tolazamide, in the same dosages de-
scribed for rats for 26 weeks. Tolazamide, low- or high-
dosage, did not improve hyperglycemia (Fig. 6). As in
the studies in rats above, renal specimens were scored
for the presence of glomerulosclerosis by three indepen-
dent observers who were masked as to the origin of the
specimens. The mean total number of glomeruli scored
per animal by the three observers was 160 ± 70 (mean,
SD) without significant differences between experimen-
tal groups. As before, there was also a high overall re-
liability for the three observers averaged together (in-
terrater reliability coefficient 0.92). The total number of
scores generated was 13,346. The mean percent of scle-
rotic glomeruli determined in individual animals by the
three observers was calculated and results are presented
in Figure 6. Obese diabetic mice demonstrated a signifi-
cantly higher prevalence of glomerulosclerosis compared
to lean controls, and this observation was associated with
enhanced albumin excretion (Fig. 6). In contrast to the ef-
fects in insulin-deficient rats, tolazamide did not alter the
degree of glomerulosclerosis, even when it was adminis-
tered in high dosage. Further, tolazamide administration
did not decrease the elevated levels of albumin excretion.
Additional similar studies were carried out also in a sep-
arate group of db/db mice and their controls at 18 weeks
of diabetes (not shown). Although at this shorter period
the degree of glomerulosclerosis and albuminuria in both
diabetic and age-matched control mice were significantly
lower than at 26 weeks, diabetic animals still presented
significantly greater glomerulosclerosis than controls (P
< 0.001). In addition, and as shown in the previous group,
there were no differences between tolazamide-treated
and nontreated diabetic animals (P = 0.85).
DISCUSSION
To envision the potential effects of glomerular a-
endosulfine up-regulation in diabetes, this study has in-
vestigated sulfonylureas as exogenous mimics of this
sulfonylurea-like intracellular protein. A model of
insulin-deficient diabetes offered the opportunity of test-
ing the glomerular effects of these drugs independently of
their action on insulin secretion and in a setting of severe
hyperglycemia. As expected, in streptozotocin-diabetic
rats, sulfonylureas did not alter ambient glycemia levels
or the decreased weight gain at any of the periods of
diabetes studied. In this work, two extensively adminis-
tered forms of sulfonylureas were used in dosages equiv-
alent to those within the therapeutic range in humans.
In this regard, simply factoring the dosage administered
by body weight is misleading. It has been extensively re-
ported that humans metabolize drugs much slower than
rats with a median rat/human plasma clearance ratio per
unit body weight of 7.18 [54]. Thus, the actual human
equivalent dosage for the 0.28 mg/kg glibenclamide, used
in this study in rats, is only 0.04 mg/kg, approximating a
daily dose of 2.5 mg for the average adult.
Sulfonylureas are notable for their low incidence of
side effects. Tolazamide was developed in 1966 and shown
to have extremely low toxicity in animals with an LD50
of 5 g/kg [55]. Further, in doses of 100 mg/kg/day for 2
years, it did not cause obvious adverse effects in normal
Wistar rats, except for islet b cell hyperplasia. Therefore,
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Table 2. Characteristics of the rat experimental groups included in renal function studiesa
Diabetic
Control
Group Glibenclamide Glibenclamide (0.28 mg/kg)
Treatment None None Insulin (0.28 mg/kg) plus insulin
Number 10 14 13 14 17
Blood glucose mg/dLb 93 ± 3.8c 463 ± 12.8 243 ± 22.3d 464 ± 7.6 316 ± 11.0d
Glycosylated hemoglobin% 5.0 ± 0.14c 14.6 ± 0.37 8.4 ± 0.61d,e 14.9 ± 0.46 9.1 ± 0.35d,e
Final weight g 313 ± 5.9c 246 ± 4.6 295 ± 6.2d,f 240 ± 5.8 289 ± 4.6d,f
aValues are mean ± SE.
bValue for each individual animal is the mean of all measurements over the 14-week period of observation.
cBlood glucose concentration, glycosylated hemoglobin and body weight in all diabetic groups vs. control (P < 0.001).
dBlood glucose concentration, glycosylated hemoglobin and body weight in all diabetic insulin-treated groups vs. noninsulin-treated (P < 0.001).
eBlood glucose concentration and glycosylated hemoglobin in all insulin-treated groups vs. control (P < 0.001).
fBody weight in all insulin-treated groups vs. control (P < 0.032).
it is highly unlikely that the results obtained in this study
are the consequence of confounding toxic side-effects.
At 36 weeks, the degree of mesangial expansion and
glomerulosclerosis was increased in diabetic animals over
age-matched controls. Previous studies documented sig-
nificantly increased glomerulosclerosis in diabetic rats
only after 12 months of disease [56, 57]. However, in
these studies animals received partial insulin treatment
to maintain moderate hyperglycemia and high survival
rates. Regarding the effect of sulfonylureas on glomeru-
lar injury, diabetic animals treated with these drugs had
a significant reduction in the degree of sclerosis, espe-
cially in the glibenclamide- and high tolazamide-treated
groups. In these groups, the extent of sclerosis was re-
duced to levels below control, suggesting that the bene-
ficial effect of sulfonylureas may extend beyond the dia-
betic state. In previous studies, we reported a progressive
increase in the glomerular collagen content of normal
rats aging from 5 weeks to 2 years [58]. Conceivably, be-
cause of pathogenetic similarities between diabetes and
aging [59], sulfonylureas may also act as a inhibitors of
age-related glomerulosclerosis occurring predominantly
in male rats [60, 61].
The mechanism by which sulfonylureas may limit
mesangial matrix deposition remains speculative, how-
ever, the reduction of glomerular fibronectin gene ex-
pression suggests that inhibition of extracellular matrix
synthesis may play a role. Finally, the beneficial effect
of sulfonylureas on the histologic glomerular disease
was associated with complete normalization of diabetic-
induced increased albumin excretion in all sulfonylurea-
treated groups. In addition, suboptimal immunologic
reactivity for albumin was eliminated as the reason
for this observation. However, albumin excretion in
sulfonylurea-treated animals was not reduced to the lev-
els established by age-matched controls.
Glomerular hypertension and the associated me-
chanical mesangial strain are considered important
pathogenetic factors in the accumulation of mesangial
extracellular matrix, and these are aggravated by an en-
vironment of high glucose concentration [62, 63]. Since
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Fig. 5. Glomerular filtration rate (GFR) and renal hypertrophy in rats
treated with glibenclamide and suboptimal amounts of insulin. An-
imals were the same as those described in Table 2. Streptozotocin-
injected rats were given daily doses of NPH-insulin to maintain partial
metabolic control or left untreated for 14 weeks. Groups of untreated
and insulin-treated animals were also given a daily glibenclamide dose.
GFR was determined in unanesthetized, unrestrained rats according
to the clearance of fluorescein isothiocyanate (FITC)-inulin. Calcula-
tions were based on FITC-inulin excretion in two consecutive 24-hour
urine collections and plasma concentration in tail blood samples at the
start, and end of the urine collection periods. The combined weight of
both kidneys was obtained at the conclusion of the experimental period.
Values are mean ± SE.
glibenclamide could reduce glomerular hypertension and
hyperfiltration by normalizing diabetic-induced affer-
ent arteriolar hypocontractility [23], a functional effect
was a plausible mechanism for the glomerulo-protective
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Fig. 6. Effect of treatment with sulfonylureas on the development of
glomerulosclerosis in long-term diabetic db/db mice. Obese diabetic
mice and lean normal controls entered the study at 4 to 6 weeks old
and studies performed 26 weeks later. Diabetic animals received by
gavage a daily dose of tolazamide, in the dosages indicated, during the
last 24 weeks of the experimental period. As in studies in rats (Figure
1), the degree of mesangial expansion, basement membrane thickening
and glomerulosclerosis was independently assessed by three observers,
who were masked as to the origin of the sample, in periodic acid-Schiff
(PAS)-stained specimens. The degree of glomerular disease was defined
on a scale of 0 to 4+. The individual findings by the three observers were
combined and presented as the percent of glomeruli showing conclusive
disease. Albuminuria data correspond to samples obtained at the end
of the observation period. Each individual albumin excretion value was
the mean of two 24-hour urine collections. Values presented are mean ±
SE (N = 11 to 17 animals per experimental group).
properties of sulfonylureas in diabetes. This possibility
was explored in unanesthetized, unrestrained diabetic an-
imals by measuring GFR under conditions of severe or
moderate hyperglycemia. Contrary to historical studies
in anesthetized rats, but in agreement with more recent
observations in conscious animals with blood glucose of
360 to 530 mg/dL [64, 65], it was shown that noninsulin
treated diabetic rats with marked hyperglycemia devel-
oped hyperfiltration. Nevertheless, this alteration, and
the concomitant renal hypertrophy was not modified by
glibenclamide administration, regardless of whether an-
imals were receiving suboptimal insulin treatment and
demonstrating milder glomerular hyperfunction and re-
nal hypertrophy. Thus, the preventive effects of sulfony-
lureas on the development of glomerulosclerosis are
unlikely to be related to improved afferent arteriolar
contractility.
Since sulfonylureas did not diminish hyperglycemia,
diabetic hyperfiltration, or the characteristic renal hy-
pertrophy, the glomerular effects elicited by these drugs
occurred in a setting wherein the major pathogenetic
mechanisms of diabetic glomerular injury were not cor-
rected (i.e., high glucose concentration, glomerular hy-
perfiltration, and renal hypertrophy [42, 66–71]).
The results of this study suggest that the glomerular
effects of sulfonylureas in diabetes are due to a direct
metabolic effect, possibly by interrupting or modulat-
ing signaling pathways through which glucose exerts its
stimulating effects on extracellular matrix synthesis. This
would be in consonance with the postulated mechanism
of action of a-endosulfine. Since activation of the protein
kinase C/mitogen-activated protein kinase cascade plays
a major role in the mediation of the glomerular injurious
effects of high glucose [72, 73], this pathway appears as
a likely target for sulfonylurea action. This postulate is
supported by preliminary results from our laboratory in
mesangial cells in tissue culture treated with low concen-
trations of glibenclamide [abstract; Cortes P, et al, J Am
Soc Nephrol 14:129A, 2003].
The glomerular effects of long-term sulfonylurea ad-
ministration suggest that up-regulation of a-endosulfine
expression in mesangial cells may attenuate the stimulat-
ing effects of high glucose concentrations on the forma-
tion and deposition of extracellular matrix. However, the
interplay between a-endosulfine and its exogenous coun-
terparts remains speculative. An attractive possibility is
that the effects of sulfonylureas are, at least in part, me-
diated by the up-regulation of mesangial cell ENSA and
a-endosulfine expression (unpublished observations).
The long-term administration of tolazamide did not al-
ter the degree of glomerular disease or albuminuria in
an animal model of type 2 diabetes. However, in this
model, sulfonylureas failed to improve hyperglycemia.
These findings suggest that the glomerular effects of sul-
fonylureas differ in insulin-deficient and insulin-resistant
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diabetes, unless these drugs effectively improve glu-
cose levels. In agreement with this postulate are results
from controlled clinical studies. The United Kingdom
Prospective Diabetes Study (UKPDS) determined the
incidence of microvascular complications in type 2 dia-
betic patients that were treated by either conventional
means (dietary modification), intensive therapy with one
of three sulfonylureas (chlorpropamide, glipizide, and
glibenclamide), a biguanide (metformin), or insulin [74,
75] This study demonstrated a reduction in the progres-
sion of albuminuria and renal insufficiency in all the inten-
sively treated groups. However, no significant differences
among these groups were shown, suggesting that sulfony-
lureas do not specifically alter the course of nephropathy
other than by correcting the metabolic state.
CONCLUSION
This study demonstrates that the long-term ad-
ministration of low-dosage sulfonylureas, particularly
glibenclamide, prevents the development of glomeru-
losclerosis and albuminuria in experimental, insulin-
deficient diabetes. This effect takes place independently
of hyperglycemia, glomerular hyperfunction, or renal
hypertrophy. Results suggest that up-regulation of the
mesangial SUR endogenous ligand, a-endosulfine, may
be a suppressor of the glucose-enhanced accumulation of
mesangial matrix. In regard to the potential therapeutic
use of sulfonylureas, clinical testing will be required to
demonstrate that these drugs also prevent nephropathy
in human type 1 diabetes.
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